Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadimastem reports positive ALS cell therapy results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx\u00ae Phase 1\/2a Clinical Trial in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Results of Cohort B of its Phase 1\/2a Clinical Trial of AstroRx\u00ae for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadimastem Granted a Patent in Israel for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Kadimastem","sponsor":"iTolerance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iTolerance, Inc. and Kadimastem Enter into Collaboration Agreement for Development of a Potential Cure for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"Kadimastem","sponsor":"iTolerance","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Kadimastem

    Menu

    Kadimastem

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Kadimastem

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              iTolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Ty...

              Details:

              iTOL-102 is our lead program that is developed Using our proprietary SA-FasL biotin-PEG microgel platform, which being developed as a potential cure for Type 1 Diabetes without the need for chronic immunosuppression.

              Lead Product(s): Allogeneic Stem Cell-derived Pancreatic Islets

              Therapeutic Area: Endocrinology Product Name: iTOL-102

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Recipient: iTolerance

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kadimastem

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              iTolerance, Inc. and Kadimastem Enter into Collaboration Agreement for Development of a Potential Cure for Type 1 Diabetes

              Details:

              Under the agreement, Kadimastem will supply its advanced cell product, IsletRx and iTolerance will provide its iTOL-100 immunomodulatory technology for the development of iTOL-102 (allogenic pancreatic islet cell) for the treatment of Type 1 Diabetes.

              Lead Product(s): Allogenic Pancreatic Islet Cell

              Therapeutic Area: Endocrinology Product Name: iTOL-102

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Recipient: iTolerance

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kadimastem

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kadimastem Granted a Patent in Israel for the Treatment of ALS

              Details:

              Kadimastem’s flagship product, AstroRx®, is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells and is in clinical development as a therapeutic treatment for ALS.

              Lead Product(s): Human pluripotent stem cells

              Therapeutic Area: Neurology Product Name: AstroRx

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kadimastem

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS

              Details:

              The primary objective of the trial was to evaluate the safety of AstroRx®, an "off-the-shelf", clinical-grade, astrocyte cell product, developed and manufactured by the Company. The trial met its endpoints.

              Lead Product(s): Human astrocytes

              Therapeutic Area: Neurology Product Name: AstroRx

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kadimastem

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS

              Details:

              Kadimastem's lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company’s Phase 1/2a clinical trial in ALS.

              Lead Product(s): Human astrocytes

              Therapeutic Area: Neurology Product Name: AstroRx

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kadimastem

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kadimastem reports positive ALS cell therapy results

              Details:

              A statistically significant decline in disease progression was observed during the first 3- 4 months post-treatment period, indicating a clinical benefit of the AstroRx® cell product.

              Lead Product(s): AstroRx

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY